Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AVTX-002 · CERC-002, AEVI-002

Other · developed by Avalo Therapeutics

Phase 2 Most advanced trial (none active)

AVTX Developer

1 Registered trials

What is AVTX-002?

AVTX-002 is a drug studied subcutaneously at 600 mg three times during the study. It is studied in non-eosinophilic asthma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: CERC-002, AEVI-002
Drug type: Other
Therapy area: Respiratory
Developer: Avalo Therapeutics, Inc. (AVTX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: M46KZB8QXL

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05288504	Phase 2	Non-Eosinophilic Asthma	Completed	AVTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-Eosinophilic Asthma

More from Avalo Therapeutics

AVTX-009 Phase 2 Camoteskimab Phase 1 CERC-006 Phase 1 CERC-301 Phase 2 FP01 Phase 2

Sources

ClinicalTrials.gov NCT05288504

Updated Oct 11, 2026. Something wrong or missing? Report it on the AVTX page.

Follow AVTX, the company behind AVTX-002

See AVTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AVTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z